Titan Biotech Ltd Sets February 20, 2026 as Record Date for 1:5 Equity Share Split
Titan Biotech Ltd has set February 20, 2026, as the record date for its equity share split. Each existing share with face value of ₹10.00 will be subdivided into five shares of ₹2.00 each in a 1:5 ratio. This corporate action will increase the number of shares while maintaining the total value of existing shareholdings.

*this image is generated using AI for illustrative purposes only.
Titan Biotech Ltd has announced a significant corporate action with the setting of February 20, 2026, as the record date for its equity share split. This development represents a strategic move by the pharmaceutical company to restructure its share capital.
Share Split Details
The company has outlined the specific parameters of the share subdivision:
| Parameter: | Details |
|---|---|
| Record Date: | February 20, 2026 |
| Split Ratio: | 1:5 |
| Current Face Value: | ₹10.00 per share |
| New Face Value: | ₹2.00 per share |
| Shares Received: | 5 shares for every 1 held |
Impact on Shareholders
Under this arrangement, existing shareholders will receive five new equity shares of ₹2.00 face value for every one share of ₹10.00 face value they currently hold. The total value of shareholding will remain unchanged immediately after the split, but the number of shares will increase proportionally.
Corporate Action Timeline
With the record date set for February 20, 2026, shareholders who hold shares on this date will be eligible for the share split. The company has provided advance notice of this corporate action, allowing sufficient time for shareholders to plan accordingly.
Share splits are commonly implemented by companies to enhance share liquidity and make shares more affordable for retail investors, potentially broadening the shareholder base.
Historical Stock Returns for Titan
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.06% | +3.64% | +4.03% | +9.49% | +24.52% | +159.96% |
















































